CYPHER Stent Continues to Prove Its Worth

Susan Farley
Published Online: Friday, June 1, 2007

A clinical trial comparing stents found that the CYPHER Sirolimus-eluting Coronary Stent had a clinical benefit similar to that of a bare metal stent (BMS), with no differences in incidence of heart attack, death, or blood clots. Data from this new trial support data from a previous trial touting CYPHER?s benefits. In fact, this trial showed that patients in the CYPHER group had significantly lower rates of target vessel failure at the 5-year follow-up than patients in the BMS group (22.5% vs 34.7%). At the long-term follow-up, the CYPHER stent also resulted in lower rates of re-treatment, myocardial infarction, and death, when compared with BMS (9.4% vs 24.2%).

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Latest Articles
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Latest Issues